Reference · For research
Peptide dosage chart
Commonly referenced research dosing protocols for each peptide on this site, in one place. Tap a peptide for how it works, side effects and the studies behind it. To turn a dose into units, use the dosage calculator; to prepare a vial, see how to mix peptides.
| Peptide | Research protocol |
|---|---|
| Semaglutide | Weeks 1-4: 0.25 mg once weekly Weeks 5-8: 0.5 mg once weekly Weeks 9-12: 1 mg once weekly Week 13 and beyond: 2 mg once weekly |
| Tirzepatide | Weeks 1-4: 2.5 mg once weekly Weeks 5-8: 5 mg once weekly Weeks 9-12: 7.5 mg once weekly Weeks 13-16: 10 mg once weekly Weeks 17-20: 12.5 mg once weekly Week 21 and beyond: 15 mg once weekly |
| Retatrutide | Weeks 1-4: 1.5 mg once weekly Weeks 5-8: 3 mg once weekly Weeks 9-12: 6 mg once weekly Weeks 13-16: 8 mg once weekly Weeks 17-20: 10 mg once weekly Week 21 and beyond: 12 mg once weekly |
| Cagrilintide | Weeks 1–2: 0.6 mg/week Weeks 3–4: 1.2 mg/week Weeks 5–6: 2.4 mg/week Weeks 7 and beyond: 4.8 mg/week |
| 5-Amino-1MQ | Week 1: 0.5 - 1 mg daily Weeks 2-3: 2 mg daily Week 4 and beyond: Up to 5 mg daily |
| NAD⁺ (buffered) | 50 mg twice weekly (no up-titration needed) |
| Tesamorelin | Weeks 1-2: 0.5 mg every night Weeks 3-4: 1 mg every night Weeks 5 and beyond: 2 mg every night |
| Sermorelin | Week 1: 100 mcg (0.1 mg) daily Week 2: 200 mcg (0.2 mg) daily Week 3 and beyond: 300 mcg (0.3 mg) daily |
| Ipamorelin | Week 1: 100 mcg (0.1 mg) daily Week 2: 100 mcg (0.1 mg) twice daily, for 200 mcg (0.2 mg) total every day Week 3 and beyond: 150 mcg (0.15 mg) twice daily, for 300 mcg (0.3 mg) total every day |
| CJC-1295 | CJC-1295 without DAC, week 1: 100 mcg (0.1 mg) daily CJC-1295 without DAC, week 2: 200 mcg (0.2 mg) daily CJC-1295 without DAC, week 3: 300 mcg (0.3 mg) daily CJC-1295 without DAC, weeks 4 and beyond: 400 mcg (0.4 mg) daily CJC-1295 with DAC, weeks 1-2: 1 mg weekly CJC-1295 with DAC, weeks 3 and beyond: 2 mg weekly |
| CJC-1295 / Ipamorelin blend | Week 1: 0.2 mg daily total (0.1 mg of each component daily) Week 2: 0.4 mg daily total (0.2 mg of each component daily) Week 3: 0.6 mg daily total (0.3 mg of each component daily) Weeks 4 and beyond: 0.8 mg daily total (0.4 mg of each component daily) |
| BPC-157 | Weeks 1-4: 250 mcg/day (0.25 mg/day) Weeks 5 and beyond: 500 mcg/day (0.50 mg/day) |
| TB-500 | Weeks 1-4 (treatment phase): 2.5 mg twice weekly Week 5 and beyond (maintenance phase): 0.25 mg/day |
| Thymosin β4 (TB4) | Weeks 1-2: 0.5 mg daily Week 3 and beyond: 1 mg daily |
| BPC-157 / TB4 blend | Week 1: 0.5 mg of each daily (1 mg total) Weeks 2 and beyond: 1 mg of each daily (2 mg total) |
| KPV | Weeks 1-2: 100 mcg (0.1 mg) daily Weeks 3-4: 200 mcg (0.2 mg) daily Weeks 5-6: 400 mcg (0.4 mg) daily Week 7 and beyond: 500 mcg (0.5 mg) daily |
| GHK-Cu | Weeks 1-2: 1 mg/day Weeks 3-4: 2 mg/day Weeks 5 and beyond: 3 mg/day |
| Afamelanotide (Melanotan I) | First 10 days (loading phase): 0.25 – 0.5 mg once daily Day 11 and beyond (maintenance phase): 0.5 mg – 1 mg once weekly, depending on desired effect |
| Melanotan II | Weeks 1-2 (loading phase): 0.5 mg/day Week 3 and beyond (maintenance phase): 0.25 mg/day |
| GLOW blend | Week 1: 2 mg daily (2 mg total, which adds up to 1.42 mg GHK-Cu and 0.285 mg of each of BPC-157 and TB4 (or TB-500)) Week 2 and beyond: 4 mg daily (4 mg total, which adds up to 2.84 mg GHK-Cu and 0.57 mg of each of BPC-157 and TB4 (or TB-500)) |
| KLOW blend | Week 1: 2 mg daily (2 mg total, which adds up to 1.25 mg GHK-Cu and 0.25 mg of each of KPV, BPC-157, and TB4 (or TB-500)) Week 2 and beyond: 4 mg daily (4 mg total, which adds up to 2.5 mg GHK-Cu and 0.50 mg of each of KPV, BPC-157, and TB4 (or TB-500)) |
| PT-141 (bremelanotide) | 1.75 mg injected subcutaneously 45 minutes - 1 hour before anticipated sexual activity |
| N-Acetyl Semax Amidate | Weeks 1-2: 0.3 mg (300 mcg) daily Weeks 3-4: 0.5 mg (500 mcg) daily Week 5 and beyond: Up to 1 mg daily |
| DSIP | Weeks 1-2: 0.2 mg (200 mcg) 30-60 minutes before bed Weeks 3 and beyond: 0.5 mg (500 mcg) 30-60 minutes before bed |
| MOTS-c | 5 mg twice weekly, every week (no up-titration) |
| Epithalon | While no standard dosage has been established, a common research dosing protocol for epithalon is 5 mg daily, administered by injection under the skin (subcutaneous) |
For education only These are protocols reported in research settings, not dosing recommendations. Many of these peptides are not FDA-approved. A licensed clinician should set any actual dose.